Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL

NCT02361346 is registered in ClinicalTrials.gov with Molecular Templates, Inc. as lead sponsor.

NCT NCT02361346
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02361346 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
Lead sponsor
Molecular Templates, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
February 28, 2015
Completion date
March 22, 2021
Enrollment
38 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

blood cancer, diffuse large b cell lymphoma, hematological malignancy, leukemia, lymphocytic, chronic, b-cell, non-hodgkin's b-cell lymphoma, small lymphocytic leukemia